JAK1 and colorectal carcinoma: Conversely, preclinical inhibition of JAK1/2 or STAT3 has been shown to restore chemosensitivity to 5-FU and oxaliplatin, supporting the pathway as a potential therapeutic target for chemoresistant CRC [30,44].